UBE2I and breast carcinoma: UBC9, the sole SUMO E2 conjugating enzyme, may induce tumor cell resistance to chemotherapy via upregulating expression of anti-apoptotic protein Bcl-2 and is correlated with poor clinical prognosis in breast cancer [139, 140, 142].